Expression and Clinical Significance of PRAME and WT1 Gene in Patients with Acute Leukemia
FAN Xiao-ju,LI Hui-hui,LIANG Chang-da,TANG Ai-ping,FEI Yan
DOI: https://doi.org/10.3969/j.issn.1000-2294.2008.01.014
2008-01-01
Abstract:Objective To investigate and discuss the expression and clinical significance of WT1 and PRAME in the mononuclearcells of patients with acute leukemia(AL).Methods The levels of WT1 and PRAME were measured by semiquantitative reverse transcription polymerase chain reaction(RT-PCR) method in 54 AL patients,and then the results were compared between two groups.Results The positive rate of PRAME in mononuclearcells of ANLL patients was 41.9%,while All patients was 38.5%,the differences of two groups were not significant(P0.05).The positive rate of WT1 in mononuclearcells of ANLL patients was 48.4%,while ALL patients was 46.2%,the differences of two groups were not significant(P0.05).The expression of PRAME and WT1 in CR group and normal-control subjects were all negative.The levels of PRAME and WT1 of effective group were significantly lower than those of ineffective group(P0.01).We had followed up 11 AL PRAME+ patients,and among of they,one was of WT1-,ten were of WT1+,and the levels of PRAME were persistently higher in 7 patients after chemotherapy.The levels of PRAME of 4 relapse patients increased again before relapse,and the levels of WT1 of 2 patients increased synchronously,while those of anthor 2 increased again when relapse.Conclusion As WT1 gene,PRAME is a marker gene of acute leukemia.Dynamically detecting the change of PRAME can make us to comprehend development of disease and loading of leukemia cells,and then can predict relapse,monitor minimal resiolnal disease(MRD),and direct us to prevent and cure relapse.